FY2025 EPS Estimates for Alumis Increased by Leerink Partnrs

Alumis Inc. (NASDAQ:ALMS) – Investment analysts at Leerink Partnrs lifted their FY2025 earnings per share estimates for Alumis in a research report issued to clients and investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now forecasts that the company will post earnings of ($4.79) per share for the year, up from their previous forecast of ($5.19). The consensus estimate for Alumis’ current full-year earnings is ($8.45) per share. Leerink Partnrs also issued estimates for Alumis’ FY2026 earnings at ($4.67) EPS, FY2027 earnings at ($5.70) EPS and FY2028 earnings at ($3.56) EPS.

A number of other equities analysts have also weighed in on the stock. Robert W. Baird started coverage on shares of Alumis in a research report on Thursday, October 31st. They set an “outperform” rating and a $25.00 target price for the company. Oppenheimer initiated coverage on shares of Alumis in a research note on Thursday, January 30th. They issued an “outperform” rating and a $32.00 price objective for the company. Baird R W raised shares of Alumis to a “strong-buy” rating in a report on Thursday, October 31st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Alumis in a report on Thursday, November 14th. Finally, HC Wainwright reiterated a “buy” rating and set a $26.00 price objective on shares of Alumis in a research note on Monday, January 6th. Seven research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Alumis currently has a consensus rating of “Buy” and an average target price of $27.57.

Alumis Price Performance

Shares of ALMS opened at $6.59 on Friday. Alumis has a fifty-two week low of $6.29 and a fifty-two week high of $13.53. The business has a 50-day moving average of $7.93 and a 200 day moving average of $10.30.

Institutional Investors Weigh In On Alumis

Large investors have recently added to or reduced their stakes in the business. Samsara BioCapital LLC purchased a new stake in shares of Alumis in the 3rd quarter valued at about $34,886,000. Towerview LLC raised its position in shares of Alumis by 9.2% during the 4th quarter. Towerview LLC now owns 415,000 shares of the company’s stock valued at $3,262,000 after buying an additional 35,000 shares in the last quarter. Geode Capital Management LLC bought a new stake in shares of Alumis during the 3rd quarter worth $3,266,000. Millennium Management LLC purchased a new position in Alumis in the second quarter worth $3,376,000. Finally, Charles Schwab Investment Management Inc. increased its stake in Alumis by 4.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 113,401 shares of the company’s stock valued at $891,000 after acquiring an additional 4,808 shares during the last quarter.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.